Restoration of defective cross-presentation in tumors by gemcitabine

Alison M McDonnell1, W Joost Lesterhuis1, Andrea Khong1

  • 1School of Medicine and Pharmacology; The University of Western Australia ; Nedlands, WA, Australia ; National Centre for Asbestos Related Diseases ; Nedlands, WA, Australia.

Oncoimmunology
|July 9, 2015
PubMed

Tumor antigen cross-presentation by dendritic cells (DCs) to specific CD8+ T cells is central to antitumor immunity. Although highly efficient in draining lymph nodes, it is defective within the tumor site itself. Importantly, an immunogenic chemotherapy, gemcitabine, reverses this defect, allowing the potential re-stimulation of cytotoxic T lymphocytes within tumor sites.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K